# Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

> **NCT05517239** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 32 (actual)

## Conditions studied

- Hepatocellular Carcinoma, Unresectable, Advanced

## Interventions

- **DRUG:** Gemcitabine, Oxaliplatin

## Key facts

- **NCT ID:** NCT05517239
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-01
- **Primary completion:** 2019-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05517239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05517239, "Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05517239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*